Exeliom Biosciences

Executive Summary

Exeliom Biosciences is a French biotech company pioneering novel therapeutic approaches that harness the microbiome-host interaction to combat immune-mediated diseases, with an initial focus on inflammatory bowel diseases (IBD). Founded in 2016 and headquartered in Paris, the company is advancing a pipeline of biologics designed to modulate the gut microbiome and restore immune homeostasis. Its lead candidate is in Phase 2 clinical development for IBD, targeting a significant unmet medical need given the limited efficacy and tolerability of current treatments. Exeliom's platform leverages proprietary knowledge of key microbial players to develop first-in-class therapies that address the root causes of chronic inflammation.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for lead candidate in IBD45% success
• Q3 2026Regulatory designation (e.g., FDA Fast Track or Orphan Drug) for lead program70% success
• H2 2026Potential partnership or licensing deal for ex-European rights55% success